- Home
- CDNA vs DFIN Comparison
CDNA vs DFIN Comparison
Compare CDNA & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- DFIN
- Stock Information
- Founded
- CDNA 1998
- DFIN 1983
- Country
- CDNA United States
- DFIN United States
- Employees
- CDNA N/A
- DFIN N/A
- Industry
- CDNA Medical Specialities
- DFIN Other Consumer Services
- Sector
- CDNA Health Care
- DFIN Consumer Discretionary
- Exchange
- CDNA Nasdaq
- DFIN Nasdaq
- Market Cap
- CDNA 1.0B
- DFIN 1.2B
- IPO Year
- CDNA 2014
- DFIN N/A
- Fundamental
- Price
- CDNA $19.04
- DFIN $59.76
- Analyst Decision
- CDNA Buy
- DFIN Strong Buy
- Analyst Count
- CDNA 6
- DFIN 3
- Target Price
- CDNA $30.33
- DFIN $68.67
- AVG Volume (30 Days)
- CDNA 996.2K
- DFIN 222.2K
- Earning Date
- CDNA 07-30-2025
- DFIN 07-30-2025
- Dividend Yield
- CDNA N/A
- DFIN N/A
- EPS Growth
- CDNA N/A
- DFIN N/A
- EPS
- CDNA 1.07
- DFIN 3.01
- Revenue
- CDNA $346,421,000.00
- DFIN $779,600,000.00
- Revenue This Year
- CDNA $13.31
- DFIN $1.99
- Revenue Next Year
- CDNA $15.46
- DFIN $4.64
- P/E Ratio
- CDNA $17.61
- DFIN $20.02
- Revenue Growth
- CDNA 25.92
- DFIN N/A
- 52 Week Low
- CDNA $13.48
- DFIN $37.80
- 52 Week High
- CDNA $34.84
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- CDNA 55.64
- DFIN 69.95
- Support Level
- CDNA $18.51
- DFIN $56.29
- Resistance Level
- CDNA $19.62
- DFIN $60.64
- Average True Range (ATR)
- CDNA 0.84
- DFIN 1.13
- MACD
- CDNA 0.02
- DFIN 0.13
- Stochastic Oscillator
- CDNA 66.12
- DFIN 87.99
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.